The risk of Graft-Versus-Host Disease (GVHD) varies with different myeloablative regimens: IV Busulfan/Fludarabine (IV BuFlu) versus IV Busulfan/Cyclophosphamide (IV BuCy) versus Fludarabine/Melphalan (FM)  by Mickler, K.L. et al.
care of the pheresis catheter; (3) describe the standards for dosing,
frequency, and administration of GCSF; (4) provide education
about the possible side effects of granulocyte donation and how
they may be prevented; (5) describe the potential emotional impli-
cations for the donor.
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NURSING CONSIDERATIONS FOR BMT PHOTOPHERESIS PATIENTS
Rhodes, B.A. M. D. Anderson Cancer Center, Houton, TX.
Graft-versus-Host Disease (GVHD) is a common complication and
limitation of allogeneic hematopoietic stem cell transplantation.
GVHD has a profound impact on the patient’s quality of life and long
term survival rate. Conventional therapy for GVHD is often associ-
ated with signiﬁcant side effects and treatment related complications.
Research is ongoing to ﬁnd better ways to treat GVHD. One treat-
ment modality that appears promising is photopheresis or extracor-
poreal photochemotherapy. Recent studies have shown photopheresis
to have efﬁcacy for the treatment of GVHD of skin, liver, lung, oral
mucosa, and eyes. Photopheresis is an immunomodulatory therapy
that utilizes the leukapheresis of white blood cells, methoxsalen, and
ultraviolet light. Photopheresis was approved by the Food and Drug
Administration in 1988 for the treatment of Cutaneous T-Cell Lym-
phoma. Many photopheresis procedures have been successfully per-
formed on this patient population without complications. The BMT
patient with GVHD is a complex patient with issues such as anemia,
thrombocytopenia, and immunosuppression. These issues can in-
crease the complexity and complications of any procedure. Our center
currently performs approximately 150 photopheresis treatments per
month. Nursing guidelines have been established to minimize and
prevent complications to provide a safe and effective treatment for this
complex patient population. Patient education, order sets, progress
notes, and procedure worksheets were also developed to streamline
the procedure. Photopheresis appears to be an exciting and promising
therapy for the treatment of some forms of GVHD. Nursing guide-
lines and interventions can make a difference to ensure a successful
photopheresis treatment.
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ACUTE HYPERTENSIVE CRISIS DURING INFUSION OF HEMATOPOIETIC
PROGENITOR CELL FROM MATCHED UNRELATED DONORS: IDENTIFI-
CATION OF PREDICTIVE FACTORS AND OPTIMAL TREATMENT
Blackburn, R.K., Giralt, S.A., Saliba, R.M., Rondon, G., Fenwick, J.N.
UTMDACC, Houston, TX.
Background: Acute hypertensive crisis during autologous hemato-
poietic progenitor cell (HPC) infusions using DMSO is widely re-
ported, but the literature is silent regarding this event during infusions
of HPC from matched unrelated donors (MUD). MUD-HPC infu-
sions are often given by evening nursing staff when there is less clinical
support in the hospital, and treatment varies with physician prefer-
ence. Identiﬁcation of predictive factors and of optimal treatment may
lead to improved outcomes. Purpose: To identify predictive factors
for the development of acute hypertensive crisis, and to develop best
treatment pathways. Methods: A retrospective review of 97 adult
patients receiving MUD HPC infusions from October 2003 to Sep-
tember 2004 was done. Demographic, clinical, and laboratory factors
were evaluated for the occurrence of hypertensive crisis using regres-
sion analysis. This analysis was limited to patients receiving HPC-
marrow infusions because only 2/20 cases occurred among patients
receiving PBSC. Hypertensive crisis was deﬁned as SBP 	 160,
DBP 	 100, or a symptomatic increase in BP of 20 mm HG 	
baseline.Results:On univariate analysis, volume infused (adjusted for
weight), elevated creatinine (	1.0 mg/dl), and BUN levels above the
median (	15 mg/dl) were signiﬁcant predictors. Because of high
correlation between BUN and creatinine, only BUN was considered
in multivariate analysis (higher precision associated with the estimate).
Patients receiving high volume infusions with an elevated BUN were
at the greatest risk (62%), followed by patients receiving high volume
infusions and low BUN (28%), and then by patients receiving low
volume and high BUN (17%). There were no cases of hypertension
among the 18 patients who received low volumes and had a low BUN.
Medical treatment during hypertensive episodes varied but best re-
sponses were seen with combined use of IV antihypertensive agents
and diuretics. Recommendations: These ﬁndings suggest that vol-
ume reduction of HPC-M may decrease the incidence of acute hy-
pertensive crisis during MUD infusions (Table 1).
Table 1. Patient Characteristics
Continuous
variables Number
Yes HTN
Crisis
No HTN
Crisis
p
value OR
95%
CI
Age 49 (25-67) 49 (23-71) 0.9
Prior Chemo 2 (0-11) 2.5 (0-9) 0.7
Volume Infused/
Weight 20 (4-29) 6 (0.6-25) 0.001
<4 20 1 (5%)
4-9 16 2(12%)
10-20 18 6 (33%)
>20 16 9 (56%)
<9 36 3 (8%)
>9 34 15 (44%) 0.002 8.7 2.2-33.9
Weight at infusion 79 (59-119) 88 (56-158) 0.2
WBC 0.85 (0.1-5.3) 0.7 (0-15) 0.7
HGB 10.4 (7.9-14) 9.4 (7.4-8.6) 0.26
Hct 30 (22-44) 26 (20-38) 0.1
Plt 59 (4-336) 51 (1-222) 0.9
Acg 0.23 (0-5) 0.68 (0-6) 0.14
Na 139 (136-145) 139 (132-144) 0.3
K 4.1 (2.9-6.3) 3.9 (3.2-5.4) 0.7
Cl 105 (101-115) 107 (99-113) 0.9
CO2 27 (20-32) 27 (21-56) 0.7
Alb 3 (2.2-4.1) 3.1 (2.3-8.8) 0.5
Creatinine 0.95(0.5-2.8) 0.8 (0.5-2.1) 0.03
<1 57 11 (19%)
>1 13 7 (54%) 0.02 4.9 1.4-17
BUN 19 (11-67) 15 (6-71) 0.03
<12 19 2 (11%)
13-15 17 3 (18%)
16-21 19 8 (42%)
>21 15 5 (33%)
<15 36 5 (14%)
>15 34 13 (13%)
Tacro levels 11.5 (3.7-30) 10 (3.1-22.7) 0.3
Categorical
variables
Male 39 10 29
Female 31 8 23 0.9 ref. 1 0.3-2-9
Prior Allo 62 17
No Prior Allo 5 0 5
Prior Auto 11 4 7 0.4 ref 1.9 0.5-7.5
No Prior Auto 56 13 43
Hx of HTN 12 3 9
No Hx HTN 58 15 43 0.9 ref 0.9 0.2-4.0
Hx Diabetes 9 3 6 0.6 ref 1.5 0.3-6.9
No Hx Diabetes 61 15 46
Hx Cardiac Dis 14 5 9 0.3 1.8 0.5-6.5
No Hx Cardiac
Disease 56 13 43
Hx surgery 32 7 25 0.5 ref 0.7 0.2-2.0
No Hx Surgery 38 11 27
Hx Renal disease 4 2 2 0.3 3.1 0.4-24
No Hx Renal dis 66 16 50
Diuretics Used 5 1 4 0.8 0.7 0.1-6.8
No diuretics used 65 17 48
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THE RISK OF GRAFT-VERSUS-HOST DISEASE (GVHD) VARIES WITH
DIFFERENT MYELOABLATIVE REGIMENS: IV BUSULFAN/FLUDARABINE
(IV BuFlu) VERSUS IV BUSULFAN/CYCLOPHOSPHAMIDE (IV BuCy)
VERSUS FLUDARABINE/MELPHALAN (FM)
Mickler, K.L., Saliba, R., Ghosh, S., de Lima, M., Giralt, S., Kim, S.,
Andersson, B., Khouri, I., Champlin, R.E., Couriel, D. The University
of Texas M.D. Anderson Cancer Center, Houston, TX.
Objective: To compare the incidence of GVHD and non-re-
lapse mortality (NRM) among different myeloablative preparative
Transplant Nursing
156
regimens for hematopoietic stem cell transplantation (HSCT).
Methods: Analysis of all patients who received an allogeneic,
matched-sibling (6/6) HSCT for myeloid malignancies enrolled in
4 different transplant studies between 4/97 and 12/04. These
studies included 3 preparative regimens: (1) IV Busulfan, 130
mg/m2  4 days and Fludarabine, 40 mg/m2  4 days (IVBuFlu);
(2) IV Busulfan, 0.8 mg/kg q6h  4 days and Cyclophosphamide,
60 mg/kg  2 days (IVBuCy), and (3) Fludarabine, 30 mg/m2  4
days and Melphalan, 180 mg/m2 (FM). All patients received the
same GVHD prophylaxis with tacrolimus and minidose metho-
trexate. Results: A total of 176 patients (IVBuFlu 89, IVBuCy
60, and FM  27) were analyzed, and patients’ characteristics are
summarized in Table 1. The median age was signiﬁcantly higher in
the FM group compared to the IVBuFlu and IVBuCy groups.
IVBuFlu had a signiﬁcantly higher proportion of peripheral blood
stem cell transplants (PBSCT) compared with IVBuCy, and more
patients with mixed chimerism on day 30 post transplant compared
with both IVBuCy and FM. The rate of Grade 2-4 acute GVHD
was lowest in the IVBuFlu group (18%), compared with IVBuCy
(34%, P  .01) and FM (26%, P  .2). IVBuFlu continued to have
a signiﬁcantly lower rate of Grade 2-4 acute GVHD among pa-
tients with donor chimerism. Grade 3-4 acute GVHD also favored
the IVBuFlu group (3%) in comparison with IVBuCy (12%, P 
.03) and FM (11%, P .05). The incidence of chronic GVHD was
similar in all regimens. NRM at 1 year was 9% with IVBuFlu, 17%
with IVBuCy (P .2) and 33% with FM (P .002). Conclusions:
The incidence of acute GVHD and NRM differs among myeloa-
blative regimens. These differences are only partially explained by
regimen intensity (Table1).
Table 1. Patients Characteristics
FM
(n  27)
IVBuCy
(n  60)
IVBuFlu
(n  89)
IV BuFlu
vs FM
IVBuFlu vs
IVBuCy
Median F/U (mo) 63 (38-81) 62 (19-75) 22 (6-50)
Median Age 54 40 47 P < .001 P  .06
MDS/AML 16 (59%) 36 (60%) 89 (100%)
CML 11 (41%) 24 (40%) 0
PBSC 24 (89%) 41 (68%) 76 (85%) P  .5 P  .01
Donor/Mixed
chim 81%/4% 90%/3% 62%/30% P  .05 P < .001
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THE COMPLEX CARE CHALLENGE OF TRANSPLANT PATIENTS AND
FAMILIES: HOW TO EFFECTIVELY PROMOTE CARE ACROSS THE CON-
TINUUM THROUGH ROLE DEVELOPMENT IN THE PROGRAM
Schulte, K.A., Hubner, M., Binari, E., Gaumer, C. Dana-Farber/
Brigham & Women’s Cancer Center, Boston, MA.
Topic: Ambulatory Care Coordination is a synergistic model of
care that provides assistance to transplant (BMT) patients and their
families who are high risk from a clinical and/or ﬁnancial perspec-
tive; eg, second transplant, psychosocial needs, limited ﬁnancial
and or socioeconomic resources, or limited insurance coverage.
Abstract: A multidiscipinary team inclusive of nursing leadership,
administrative leadership, research/program nurses, social workers,
and care coordination nurses had the oppurtunity to assist with the
development and implementation of a new role. This nurse’s role
would be to assist in providing a seamless continuum of patient
care between the ambulatory and inpatient setting, as a well as to
build a bridge to community and home care services. Purpose:
The purpose of this project was to design, develop, and implement
a new nursing role, the Ambulatory BMT RN Care Coordinator.
Our goal was to have this nursing role actively participate in the
pretransplant process. A large focus of the role is to identify
potential discharge issues prior to patient admission by developing
preliminary discharge plans for identiﬁed patients. Interventions:
A multidisciplinary task force met to create a job description and
role. This role was developed from discussion/feedback from in-
patient/oupatient members of nursing staff, social work, ﬁnancial
counselors, and administration. Interpretation:Monthly meetings
have been coordinated between the inpatient and outpatient
groups to evaluate the communication and process on an ongoing
basis. Monthly meetings between the Ambulatory Nurse Leader,
the program/research transplant nurses, the RN Program Manager
for Care Coordination, and the Ambulatory BMT RN Care Co-
ordinator occur in order to continually evaluate the program for its
effectiveness, ease of communication, and its ability to provide
continuous care coordination across both the ambulatory and in-
patient settings. Since inception of this program, 14 months, 225
patients have been identiﬁed and managed by the Ambulatory
BMT RN Care Coordinator. As a result of being exposed to
multiple aspects of the transplant process, this role has served to
identify process and system issues and trends in the industry, eg,
limited pharmacy beneﬁts. Discussion: The ﬁnancial, psychoso-
cial, and clinical needs of this patient population are highly com-
plex and require clear pathways of communication to achieve the
best possible patient outcomes.
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SUCCESSFUL MOBILISATION, HARVEST, AND TRANSPLANT OF STEM
CELLS FOLLOWING AMD3100 IN 3 PAEDIATRIC PATIENTS. THE AUS-
TRALIAN EXPERIENCE
Stephen, K.1, Montgomery, K.1, Bateman, C.1, Calandra, G.2,
Shaw, P.J.1 1. The Children’s Hospital at Westmead, Sydney, NSW,
Australia; 2. AnorMED, Langley, BC, Canada.
We report the successful mobilisation and subsequent transplant
of three patients, using granulocyte cell stimulating factor (GCSF)
and AMD3100, who had failed previous mobilisation attempts.
AMD3100 is a potent and selective antagonist of the CXCR4
chemokine receptor, and blocks binding of its cognate ligand,
encouraging the release of haematopoietic stem cells into the
peripheral circulation. AMD3100 was obtained on a compassionate
basis from AnorMed and given as per protocol, with a pre phase of
10mcg/kg GCSF for 4 days and AMD3100 240mcg/kg given
subcutaneously on day 5, 10-11 hours prior to apheresis and then
given daily until the required number of cells were collected. The
patients diagnoses were Ewings sarcoma, ALL, and Medulloblas-
toma. All were male patients aged between 10-17 years: the 10-
year-old being the youngest patient at the time of administration,
to have received AMD 3100. Each patient had a history of failed
mobilization following a range of regimens and between 1 to 4
attempts at mobilization prior to the commencement of
AMD3100. No side effects of treatment with AMD3100 were
noted. All were successfully collected with adequate PBSCs to
enable reinfusion after either myeloablative chemotherapy or se-
quential tandem high dose therapy (for medulloblastoma). The
Ewing’s sarcoma patient was conditioned with Busulfan/melphalan
and recovered neutrophils of 0.5 109/l after 14 days; he remained
platelet dependent as he progressed soon after BMT. The ALL
patient received total body irradiation 1320 cGy and melphalan
and recovered to neutrophils 	 0.5  109/l after 23 days and
platelets 	 50  109/l after 29 days. The patient with medullo-
blastoma received 4 courses of high dose multiagent therapy with
stem cell rescue and showed prompt haematological recovery after
each course. These three cases illustrate that AMD3100, in com-
bination with GCSF, can achieve successful mobilization and stem
cell collection in previously poorly mobilizing patients. This al-
lowed subsequent delivery of myeloablative chemotherapy fol-
lowed by autologous PBSC infusion and sustained engraftment in
these patients.
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INCREASING THE SAFETY OF PATIENT-ADMINISTERED OUTPATIENT
CONDITIONING THERAPY WITH ORAL BUSULFAN
Wickline, M.M. 1Seattle Cancer Care Alliance, Seattle, WA.
Patient-administered chemotherapy in the home is without the
controls and safeguards of nurse-administered chemotherapy in
the clinical setting. Oral Busulfan is commonly used as condition-
ing chemotherapy for patients undergoing Hematopoietic Stem
Cell transplantation (HSCT). Because the treatment schedule is
every 6 hours, and patients are usually well enough to remain
outpatient, patients at the Seattle Cancer Care Alliance self-ad-
minister Busulfan at home. Historically, this practice made it dif-
Transplant Nursing
157BB&MT
